Author

J. D. Silva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. Gazumyan· 2 shared C. Gaebler· 2 shared C. O. Barnes· 2 shared D. Schaefer-Babajew· 2 shared F. Muecksch· 2 shared F. Schmidt· 2 shared K. G. Millard· 2 shared M. C. Nussenzweig· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Gazumyan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

Nature · Jun 14, 2021Peer-reviewedImmunology

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Nature · Feb 10, 2021Peer-reviewedImmunology